Phase II study of bemnifosbuvir in high-risk participants in a hospital setting with moderate COVID-19
Arantxa Horga, Daniel R Kuritzkes, John J Kowalczyk, Keith Pietropaolo, Bruce Belanger, Kai Lin, Kristen Perkins, Janet Hammond
Future Virology, doi:10.2217/fvl-2023-0064
Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: Adults in hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study amended to two parts after interim analysis; part B enrollment limited owing to evolving standard of care. Results: Although the study ended early and did not meet the primary efficacy end point, bemnifosbuvir was well tolerated and did not contribute to allcause mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61 log 10 greater viral load mean change on day 2; trend sustained through day 8. Treatment-emergent adverse events were similar in both groups; most were mild/moderate, unrelated to study drug. Conclusion: Our results suggest a potential role for bemnifosbuvir in blunting COVID-19 progression. Clinical Trial Registration: NCT04396106 (ClinicalTrials.gov) Tweetable abstract: #Bemnifosbuvir, a novel/oral/nonmutagenic/nonteratogenic/nucleotide analogue with low DDI/resistance potential, inhibits SARS-CoV-2 replication and was well tolerated, did not contribute to all cause mortality and resulted in greater viral load mean change. Results suggest potential to blunt #COVID-19 progression.
Supplementary data To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/ suppl/10.2217/fvl-2023-0064
Author contributions All authors were involved in the development of the study protocols; in the collection, analysis and interpretation of study data; in writing of the clinical study report; and in the decision to submit the article for publication.
Ethical conduct of research The authors state that they have obtained appropriate institutional review board approval and have followed the principles outlined in the Declaration of Helsinki for all human experimental investigations. In addition, informed consent has been obtained from the participants involved.
References
Clinicaltrials, Gov, SUNRISE-3: efficacy and safety of bemnifosbuvir in high-risk outpatients with COVID-19
Clinicaltrials, Gov, Safety and efficacy of AT-527 in subjects with moderate coronavirus disease (COVID-19) in a hospital setting
Fajnzylber, Regan, Coxen, SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nat. Commun
Fusco, Shea, Lin, Health outcomes and economic burden of hospitalized COVID-19 patients in the United States, J. Med. Econ
Good, Westover, Jung, AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19, Antimicrob. Agents Chemother
Huang, Bemnifosbuvir, BEM, AT-527), a potent inhibitor of SARS-CoV-2 variants of concern (VOC), and a promising oral antiviral with a high resistance barrier for treatment of COVID-19 and other coronavirus infections
Islam, Hasan, Rahman, Islam, Comparative evaluation of authorized drugs for treating Covid-19 patients, Health Sci. Rep
Iuliano, Brunkard, Boehmer, Trends in disease severity and health care utilization during the early Omicron variant period compared with previous SARS-CoV-2 high transmission periods -United States, December 2020-January 2022, Morb. Mortal. Wkly. Rep
Jang, Choe, Yun, Reinfection with SARS-CoV-2 in general population, South Korea; nationwide retrospective cohort study, J. Med. Virol
Kip, Mccreary, Collins, Evolving real-world effectiveness of monoclonal antibodies for treatment of COVID-19: a cohort study, Ann. Intern. Med
Li, Hilgenfeld, Whitley, Clercq, Therapeutic strategies for COVID-19: progress and lessons learned, Nat. Rev. Drug Discov
Lin, Xu, Gu, Zeng, Sunny et al., Durability of bivalent boosters against omicron subvariants, N. Engl. J. Med
Marzolini, Kuritzkes, Marra, Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir/ritonavir (Paxlovid) and comedications, Clin. Pharmacol. Ther
Mazzitelli, Mengato, Sasset, Molnupiravir and nirmatrelvir/ritonavir: tolerability, safety, and adherence in a retrospective cohort study, Viruses
Paxlovid, Emergency Use Authorization Fact Sheet
Randall, Sam, Tartar, Murray, Cannon, More than 12.7 billion shots given: COVID-19 tracker
Salian, Wright, Vedell, COVID-19 transmission, current treatment, and future therapeutic strategies, Mol. Pharm
Sanderson, Hisner, Ia, Peacock, Ruis, Identification of a molnupiravir-associated mutational signature in SARS-CoV-2 sequencing databases, medRxiv,
doi:10.1101/2023.01.26.23284998Shannon, Fattorini, Sama, A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase, Nat. Commun
Soriano, De-Mendoza, Edagwa, Oral antivirals for the prevention and treatment of SARS-CoV-2 infection, AIDS Rev
Vo, Good, Agrawal, Sommadossi, Low risk of drug-drug interactions (DDIs) for bemnifosbuvir (BEM) based upon in vitro metabolism and transporter interaction studies
Wang, Yang, Song, Oral GS-441524 derivatives: next-generation inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase, Front. Immunol
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study, Lancet Infect. Dis
Zhou, Horga, Puri, AT-527 achieves antiviral concentrations in the human lung
Zhou, Morelli, Montrond, Bemnifosbuvir has low potential to interfere with P-gp, BCRP, and OATP1B1-mediated transport
Zhou, Morelli, Montround, No dose adjustments for CYP3A4 substrates when co-administered with bemnifosbuvir
{ 'indexed': {'date-parts': [[2023, 6, 24]], 'date-time': '2023-06-24T04:27:40Z', 'timestamp': 1687580860503},
'reference-count': 37,
'publisher': 'Future Medicine Ltd',
'funder': [{'name': 'Atea Pharmaceuticals'}],
'content-domain': {'domain': [], 'crossmark-restriction': False},
'abstract': '<jats:p> Background: Bemnifosbuvir, a novel, oral, nonmutagenic, nonteratogenic nucleotide '
'analogue inhibits SARS-CoV-2 replication in vitro. Materials & methods: Adults in '
'hospital settings with moderate COVID-19 were randomized 1:1 bemnifosbuvir/placebo. Study '
'amended to two-parts after interim analysis; part B enrollment limited owing to evolving '
'standard of care. Results: Although the study ended early and did not meet the primary '
'efficacy end point, bemnifosbuvir was well tolerated and did not contribute to all-cause '
'mortality. Compared with placebo, bemnifosbuvir treatment resulted in 0.61\xa0'
'log<jats:sub>10</jats:sub> greater viral load mean change on day 2; trend sustained through '
'day 8. Treatment-emergent adverse events were similar in both groups; most were '
'mild/moderate, unrelated to study drug. Conclusion: Our results suggest a potential role for '
'bemnifosbuvir in blunting COVID-19 progression. </jats:p><jats:p> Clinical Trial '
'Registration: NCT04396106 ( ClinicalTrials.gov ) </jats:p>',
'DOI': '10.2217/fvl-2023-0064',
'type': 'journal-article',
'created': {'date-parts': [[2023, 6, 23]], 'date-time': '2023-06-23T11:05:27Z', 'timestamp': 1687518327000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Phase II\xa0study of bemnifosbuvir in high-risk participants in a hospital setting with moderate '
'COVID-19',
'prefix': '10.2217',
'author': [ { 'given': 'Arantxa',
'family': 'Horga',
'sequence': 'first',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]},
{ 'given': 'Daniel R.',
'family': 'Kuritzkes',
'sequence': 'additional',
'affiliation': [ { 'name': "Brigham & Women's Hospital, Division of Infectious Disease, "
'Boston, MA\xa002115, USA'}]},
{ 'given': 'John J.',
'family': 'Kowalczyk',
'sequence': 'additional',
'affiliation': [{'name': 'American Institute of Research, Los Angeles, CA\xa090017, USA'}]},
{ 'given': 'Keith',
'family': 'Pietropaolo',
'sequence': 'additional',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]},
{ 'given': 'Bruce',
'family': 'Belanger',
'sequence': 'additional',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]},
{ 'given': 'Kai',
'family': 'Lin',
'sequence': 'additional',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]},
{ 'given': 'Kristen',
'family': 'Perkins',
'sequence': 'additional',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]},
{ 'given': 'Janet',
'family': 'Hammond',
'sequence': 'additional',
'affiliation': [{'name': 'Atea Pharmaceuticals, Boston, MA\xa002110, USA'}]}],
'member': '1057',
'published-online': {'date-parts': [[2023, 6, 23]]},
'reference': [ {'key': 'B1', 'doi-asserted-by': 'publisher', 'DOI': '10.1021/acs.molpharmaceut.0c00608'},
{'key': 'B2', 'doi-asserted-by': 'publisher', 'DOI': '10.1080/13696998.2021.1886109'},
{'key': 'B3', 'doi-asserted-by': 'publisher', 'DOI': '10.15585/mmwr.mm7104e4'},
{ 'key': 'B4',
'volume-title': 'Therapeutics and COVID-19: Living Guideline by World Health '
'Organization.',
'author': 'World Health Organization',
'year': '2021'},
{ 'key': 'B5',
'unstructured': 'FDA press release. FDA Approves First COVID-19 Vaccine. News Release. US '
'FDA (2021). '
'www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine'},
{ 'key': 'B6',
'unstructured': 'FDA press release. FDA Approves First Treatment For COVID-19. News '
'release. US FDA (2020). '
'www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19#:∼:text=Today%2C%20the%20U.S.%20Food%20and,of%20COVID%2D19%20requiring%20hospitalization'},
{ 'key': 'B7',
'unstructured': 'Randall T, Sam C, Tartar A, Murray P, Cannon C. More than 12.7 billion '
'shots given: COVID-19 tracker. Bloomberg (2022). '
'www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/'},
{'key': 'B8', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMc2302462'},
{'key': 'B9', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/jmv.28026'},
{'key': 'B10', 'doi-asserted-by': 'publisher', 'DOI': '10.7326/M22-1286'},
{'key': 'B11', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41573-023-00672-y'},
{ 'key': 'B12',
'volume': '13',
'author': 'Wang Z',
'year': '2022',
'journal-title': 'Front. Immunol.'},
{ 'key': 'B13',
'unstructured': 'CDC health advisory. COVID-19 rebound after paxlovid treatment. News '
'release. Centers for Disease Control and Prevention (2022). '
'https://emergency.cdc.gov/han/2022/pdf/CDC_HAN_467.pdf'},
{'key': 'B14', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/cpt.2646'},
{'key': 'B15', 'author': 'Sanderson T', 'year': '2023', 'journal-title': 'medRxiv'},
{ 'key': 'B16',
'unstructured': 'NIH treatment guidelines. Molnupiravir. NIH (2023). '
'www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/molnupiravir/'},
{ 'key': 'B17',
'unstructured': 'Atea Pharmaceuticals press release. Atea Pharmaceuticals reports third '
'quarter 2022 financial results and provides business update. News '
'release. Atea Pharmaceuticals (2022). '
'https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-reports-third-quarter-2022-financial'},
{'key': 'B18', 'doi-asserted-by': 'publisher', 'DOI': '10.1002/hsr2.671'},
{'key': 'B19', 'doi-asserted-by': 'publisher', 'DOI': '10.24875/AIDSRev.22000001'},
{'key': 'B20', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-022-28113-1'},
{ 'key': 'B21',
'unstructured': 'Atea Pharmaceuticals press release. Atea Pharmaceuticals reports first '
'quarter 2023 financial results and provides business update. News '
'release. Atea Pharmaceuticals (2023). '
'https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-reports-first-quarter-2023-financial'},
{ 'key': 'B22',
'volume-title': 'International Conference on Antiviral Research.',
'author': 'Huang Q',
'year': '2023'},
{ 'key': 'B23',
'volume-title': 'International Conference on Antiviral Research.',
'author': 'Vo A',
'year': '2023'},
{ 'key': 'B24',
'volume-title': 'Conference on Retroviruses and Opportunistic Infections.',
'author': 'Zhou X-J',
'year': '2023'},
{ 'key': 'B25',
'volume-title': 'Conference on Retroviruses and Opportunistic Infections.',
'author': 'Zhou XJ',
'year': '2023'},
{ 'key': 'B26',
'volume-title': 'Emergency Use Authorization Fact Sheet.',
'author': 'PAXLOVID',
'year': '2023'},
{ 'key': 'B27',
'unstructured': 'Drug–drug interactions between ritonavir-boosted nirmatrelvir (paxlovid) '
'and concomitant medications. NIH (2023). '
'www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir-paxlovid-/paxlovid-drug-drug-interactions/'},
{'key': 'B28', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.02479-20'},
{ 'key': 'B29',
'volume-title': 'The 2021 ISIRV-WHO Virtual Conference.',
'author': 'Zhou XJ',
'year': '2021'},
{ 'key': 'B30',
'unstructured': 'Clinicaltrials.Gov. Safety and efficacy of AT-527 in subjects with '
'moderate coronavirus disease (COVID-19) in a hospital setting (2020). '
'https://clinicaltrials.gov/ct2/show/NCT04396106'},
{ 'key': 'B31',
'unstructured': 'FDA. Assessing COVID-19-related symptoms in outpatient adult and '
'adolescent subjects in clinical trials of drugs and biological products '
'for COVID-19 prevention or treatment. Guidance for industry. US Food and '
'Drug Administration (2020). '
'www.fda.gov/regulatory-information/search-fda-guidance-documents/assessing-covid-19-related-symptoms-outpatient-adult-and-adolescent-subjects-clinical-trials-drugs'},
{'key': 'B32', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41467-020-19057-5'},
{'key': 'B33', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/S1473-3099(22)00507-2'},
{'key': 'B34', 'doi-asserted-by': 'publisher', 'DOI': '10.3390/v15020384'},
{ 'key': 'B35',
'unstructured': 'Atea Pharmaceuticals press release. Atea Pharmaceuticals announces U.S. '
'FDA fast track designation granted to bemnifosbuvir, an investigational '
'oral antiviral, for the treatment of COVID-19. News release. Atea '
'pharmaceuticals (2023). '
'https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-announces-us-fda-fast-track-designation-0'},
{ 'key': 'B36',
'unstructured': 'Atea Pharmaceuticals press release. Atea to advance global phase III '
'registrational study of bemnifosbuvir in high-risk non-hospitalized '
'patients with COVID-19. News release. Atea Pharmaceuticals (2022). '
'https://ir.ateapharma.com/news-releases/news-release-details/atea-advance-global-phase-3-registrational-study-bemnifosbuvir'},
{ 'key': 'B37',
'unstructured': 'Clinicaltrials.Gov. SUNRISE-3: efficacy and safety of bemnifosbuvir in '
'high-risk outpatients with COVID-19 (2022). '
'https://clinicaltrials.gov/ct2/show/NCT05629962'}],
'container-title': 'Future Virology',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://www.futuremedicine.com/doi/pdf/10.2217/fvl-2023-0064',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 6, 23]],
'date-time': '2023-06-23T11:05:42Z',
'timestamp': 1687518342000},
'score': 1,
'resource': {'primary': {'URL': 'https://www.futuremedicine.com/doi/10.2217/fvl-2023-0064'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 6, 23]]},
'references-count': 37,
'alternative-id': ['10.2217/fvl-2023-0064'],
'URL': 'http://dx.doi.org/10.2217/fvl-2023-0064',
'relation': {},
'ISSN': ['1746-0794', '1746-0808'],
'subject': ['Virology'],
'container-title-short': 'Future Virology',
'published': {'date-parts': [[2023, 6, 23]]}}
